Magewu A N, Jones P A
Department of Biochemistry and Molecular Biology, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California School of Medicine, Los Angeles 90033.
Mol Cell Biol. 1994 Jun;14(6):4225-32. doi: 10.1128/mcb.14.6.4225-4232.1994.
Cytosine methylation at CpG dinucleotides is thought to cause more than one-third of all transition mutations responsible for human genetic diseases and cancer. We investigated the methylation status of the CpG dinucleotide at codon 248 in exon 7 of the p53 gene because this codon is a hot spot for inactivating mutations in the germ line and in most human somatic tissues examined. Codon 248 is contained within an HpaII site (CCGG), and the methylation status of this and flanking CpG sites was analyzed by using the methylation-sensitive enzymes CfoI (GCGC) and HpaII. Codon 248 and the CfoI and HpaII sites in the flanking introns were methylated in every tissue and cell line examined, indicating extensive methylation of this region in the p53 gene. Exhaustive treatment of an osteogenic sarcoma cell line, TE85, with the hypomethylating drug 5-aza-2'-deoxycytidine did not demethylate codon 248 or the CfoI sites in intron 6, although considerable global demethylation of the p53 gene was induced. Constructs containing either exon 7 alone or exon 7 and the flanking introns were transfected into TE85 cells to determine whether de novo methylation would occur. The presence of exon 7 alone caused some de novo methylation to occur at codon 248. More extensive de novo methylation of the CfoI sites in intron 6, which contains an Alu sequence, occurred in cells transfected with a vector containing exon 7 and flanking introns. With longer time in culture, there was increased methylation at the CfoI sites, and de novo methylation of codon 248 and its flanking HpaII sites was observed. These de novo-methylated sites were also resistant to 5-aza-2'-deoxycytidine-induced demethylation. The frequent methylation of codon 248 and adjacent Alu sequence may explain the enhanced mutability of this site as a result of the deamination of the 5-methylcytosine.
CpG二核苷酸处的胞嘧啶甲基化被认为是导致人类遗传疾病和癌症的所有转换突变中超过三分之一的原因。我们研究了p53基因第7外显子中密码子248处CpG二核苷酸的甲基化状态,因为该密码子是种系和大多数检测的人类体细胞组织中失活突变的热点。密码子248包含在一个HpaII位点(CCGG)内,使用甲基化敏感酶CfoI(GCGC)和HpaII分析该位点及侧翼CpG位点的甲基化状态。在所检测的每个组织和细胞系中,密码子248以及侧翼内含子中的CfoI和HpaII位点均发生甲基化,表明p53基因中该区域存在广泛甲基化。用去甲基化药物5-氮杂-2'-脱氧胞苷对骨肉瘤细胞系TE85进行彻底处理,虽然诱导了p53基因相当程度的整体去甲基化,但并未使密码子248或内含子6中的CfoI位点去甲基化。将仅包含第7外显子或第7外显子及其侧翼内含子的构建体转染到TE85细胞中,以确定是否会发生从头甲基化。仅第7外显子的存在导致密码子248处发生一些从头甲基化。在转染了包含第7外显子和侧翼内含子的载体的细胞中,包含Alu序列的内含子6中的CfoI位点发生了更广泛的从头甲基化。随着培养时间延长,CfoI位点的甲基化增加,并且观察到密码子248及其侧翼HpaII位点的从头甲基化。这些从头甲基化位点也对5-氮杂-2'-脱氧胞苷诱导的去甲基化具有抗性。密码子248和相邻Alu序列的频繁甲基化可能解释了由于5-甲基胞嘧啶脱氨导致该位点突变率增加的原因。